drugset / Trial / NCT00657267
Dose-Intense Temozolomide in Recurrent Glioblastoma
Phase 2
Completed
58 enrolled
Patrick Y. Wen, MD
Brigham and Women's Hospital · collabDartmouth-Hitchcock Medical Center · collabMassachusetts General Hospital · collabSchering-Plough · collabTufts Medical Center · collabUniversity of Pennsylvania · collabWake Forest University Health Sciences · collab
NaSingle-groupOpen-labelTreatment
Summary
Temozolomide (Temodar) is an FDA approved medication for the treatment of newly diagnosed glioblastomas. In this study, we will be using temozolomide to treat recurrent glioblastomas. We will be using a different dose and schedule than the FDA approved dose and schedule. The purpose of this study is to determine if patients that have failed standard temozolomide treatment will respond to temozolomide when given at a different dose and schedule (21 days every 28 days).
Timeline
- Start
- 2008-05
- Primary completion
- 2011-11
- Completion
- 2013-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Temozolomide | Small molecule | — | Oral |